Citalopram and escitalopram in the treatment of major depressive disorder: A pooled analysis of 3 clinical trials

Annals of Clinical Psychiatry

Volumn 26, Issue 4, 2014, Pages 281-287

  Li, Huafang ^a   Li, Ting ^a   Li, Guanjun ^a   Luo, Jianfeng ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; DECREASED APPETITE; DIZZINESS; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON ANXIETY SCALE; HAMILTON DEPRESSION RATING SCALE; HEADACHE; HUMAN; INSOMNIA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; XEROSTOMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSIVE DISORDER, MAJOR; DOUBLE BLIND PROCEDURE; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84929077073     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dunlop DD, Song J, Lyons JS, et al. Racial/ethnic differences in rates of depression among preretirement adults. Am J Public Health. 2003; 93: 1945-1952.
2. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994; 151: 979-986.
3. Smith DJ, Nicholl BI, Cullen B, et al. Prevalence and characteristics of probable major depression and bipolar disorder with UK biobank: cross-sectional study of 172,751 participants. PLOS One. 2013; 25;8:e75362.
4. Gu L, Xie J, Long J, et al. Epidemiology of major depressive disorder in mainland China: a systematic review. PLOS One. 2013; 8:e65356.
5. Davidson JR Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010; 71(suppl El): e04.
6. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psycho pharmacology guidelines. J Psychopharmacol. 2008; 22: 343-396.
7. Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, et al, eds. Antidepressants: past, present and future: Handbook of experimental pharmacology. Vol 157. Berlin, Germany: Springer; 2004: 241-262.
8. Nemeroff CB, ed. Management of treatment resistant major psychiatric disorder. New York, NY: Oxford University Press; 2012.
9. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments metaanalysis. Lancet. 2009; 373: 746-758.
10. Ou JJ, Xun GL, Wu RR, et al. Efficacy and safety of escitalopram versus Citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology. 2011; 213: 639-646.
11. Garnock-Jones KP, McCormack PL. Escitalopram: a review of its use in the management of major depressive disorder in adults. CNS Drugs. 2010; 24: 769-796.
12. Matreja PS, Badyal DK, Khosla P, et al. Effectiveness and acceptability of sertraline and Citalopram in major depressive disorder: pragmatic randomized open-label comparison. Hum Psychopharmacol. 2007; 22: 477-482.
13. Langworth S, Bodlund O, Agren H. Efficacy and tolerability of reboxetine compared with Citalopram: a double-blind study in patients with major depressive disorder. J Clin Psychopharmacol. 2006; 26: 121-127.
14. Sánchez C. The pharmacology of Citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol. 2006; 99: 91-95.
15. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus Citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005; 20: 131-137.
16. Baldwin DS, Cooper JA, Huusom AK, et al. A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol. 2006; 21: 159-169.
17. Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared to Citalopram: a meta-analysis. Int J Neuro psychopharmacol. 2011; 14: 261-268.
18. Yevtushenko VY, Belous AI, Yevtushenko YG, et al. Efficacy and tolerability of escitalo pram versus Citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients. Clin Ther. 2007; 29: 2319-2332.
19. Wu EQ, Ben-Hamadi R, Lu M, et al. Treatment persistence & health costs of adult MDD patients treated with escitalopram vs. Citalopram, in a Medicaid population. Manag Care. 2012; 21: 49-58.
20. Svensson S, Mansfield PR. Escitalopram: superior to Citalopram or a chiral chimera? Psychother Psychosom. 2004; 73: 10-16.
21. Trkulja V Is escitalopram really relevantly superior to Citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J. 2010; 51: 61-73.
22. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002; 63: 331-336.
23. Lepola U, Wade A, Andersen HE Do equivalent doses of escitalopram and Citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol. 2004; 19: 149-155.
24. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; 15:CD006532.
25. Colonna L, Anderson HF, Reines EH. A randomized, double-blind, 24-weekstudy of escitalopram (10 mg/day) versus Citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin. 2005; 21: 1659-1668.
26. Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol. 2006; 21: 105-110.
27. Lam RW, Andersen HF The influence of baseline severity on efficacy of escitalopram and Citalopram in the treatment of major depressive disorder: an extended analysis. Pharmacopsychiatry. 2006; 39: 180-184.